PHAT reflux therapy targets $2B+ peak sales on strong adoption
PHAT’s gastroesophageal reflux therapy is cited as driving rapid revenue growth and profitability, with peak sales potential exceeding $2B across specialist and primary care channels, backed by pipeline expansion.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.